| CAS NO: | 252917-06-9 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 465.34 |
|---|---|
| Formula | C22H18Cl2N8 |
| CAS No. | 252917-06-9 (free base); |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 10 mg/mL warmed (21.48 mM) |
| Water: <1 mg/mL (slightly soluble or insoluble) | |
| Ethanol: <1 mg/mL (slightly soluble or insoluble) | |
| Solubility (In vivo) | 4% DMSO+30% PEG 300+ddH2O |
| Synonym | CHIR-73911 HCl; CHIR73911; CHIR 73911 hydrochloride ; CHIR-911; CHIR911; CHIR 911; CT- 99021; CT-99021; CT- 99021; GSK 3 inhibitor XVI; GSK 3IXV; CHIR99021; CHIR 99021 |
| General | Oral administration of CHIR-99021 at 30 mg/kg enhances glucose metabolism in a rodent model of type 2 diabetes, with a maximal plasma glucose reduction of nearly 150 mg/dl 3-4 hours after administration, while plasma insulin remains at or below control levels. |
|---|---|
| Animal model | Female db/db mice or male ZDF rats with type 2 diabetes |
| Formulation | Formulated as solutions in 20 mM citrate-buffered 15% Captisol or as fine suspensions in 0.5% carboxymethylcellulose. |
| Dosages | 48 mg/kg |
| Administration | Oral gavage |
| Reference | [1] Ring DB, et al. Diabetes, 2003, 52(3), 588-595. |
m.cnreagent.com